Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)

Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most patients survive less than 1 year. Aim: The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Giommoni, Elisa, Maiello, Evaristo, Vaccaro, Vanja, Rondini, Ermanno, Vivaldi, Caterina, Tortora, Giampaolo, Toppo, Laura, Giordano, Guido, Latiano, Tiziana Pia, Lamperini, Cinzia, Pillozzi, Serena, Boni, Luca, Antonuzzo, Lorenzo, Di Costanzo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161763/
https://www.ncbi.nlm.nih.gov/pubmed/34066784
http://dx.doi.org/10.3390/curroncol28030164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161763/
https://www.ncbi.nlm.nih.gov/pubmed/34066784
http://dx.doi.org/10.3390/curroncol28030164

Ejemplares similares